Deep learning-based computer-aided detection of cerebral microbleeds achieves high sensitivity with a low false-positive rate in a confirmatory clinical trial

Abstract Cerebral microbleeds (CMBs) are small, focal brain lesions recognized as critical biomarkers of cerebrovascular disease and cognitive decline. Despite advances in MRI technology, detecting CMBs remains challenging, highlighting the need for automated tools. This study aimed to evaluate the standalone performance of Neurophet SCALE MRI for automated CMB detection. The model was trained on 201 SWI and phase examinations. Neurophet SCALE MRI employs a two-stage deep learning pipeline with preprocessing steps, including reorientation, resampling, and data augmentation. In the first stage, CMB candidates are generated using a multiscale backbone and bidirectional convolutional Long Short-Term Memory. The second stage reduces false positives through a Squeeze-and-Excitation ResNet-based classifier and brain tissue segmentation. In this retrospective, single-center clinical trial, the model was tested on 457 MRI examinations. The primary endpoints were lesion-wise sensitivity (> 85.7%) and false positive rate (< 2.35 per patient). In addition, patient-wise and group-wise analyses were conducted. A total of 456 participants (224 CMB-positive, 232 CMB-negative) with 515 CMB lesions were included for the statistical analysis. The device exceeded all predefined performance criteria, demonstrating a lesion-wise sensitivity of 88.35% (95% CI: 86.61–90.17) and a false positive rate of 0.95 per patient (95% CI: 0.83–1.07). Patient-wise sensitivity and specificity were 1.0 (95% CI: 0.98–1.0) and 0.86 (95% CI: 0.81–0.90), respectively. For group-wise classification (0–4 vs. ≥5 CMBs), sensitivity and specificity were 0.91 (95% CI: 0.88–0.93) and 0.95 (95% CI: 0.74–1.0). Neurophet SCALE MRI demonstrated high sensitivity and specificity along with a low false-positive rate, supporting its potential clinical utility. Further validation by expert readers in a broader population is warranted.

Authors

Publication Details

Journal
Scientific Reports
Published
2026-11-15
DOI
https://doi.org/10.1038/s41598-026-77551-0
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Deep learning-based computer-aided detection of cerebral microbleeds achieves high sensitivity with a low false-positive rate in a confirmatory clinical trial

Jeong Taek Yoon, 송단비, Kijeong Lee, Sang-Yeong Jo et al.
Scientific Reports
Intracerebral and Subarachnoid Hemorrhage Research
article

Deep learning-based computer-aided detection of cerebral microbleeds achieves high sensitivity with a low false-positive rate in a confirmatory clinical trial

Jeong Taek Yoon, 송단비, Kijeong Lee, Sang-Yeong Jo, Min Kyoung Lee, Kyung Mi Lee, Jin San Lee, Inkeon Yeo, Eunwoo Lee, Hanna Jang, Donghyeon Kim, Hyug-Gi Kim
article en

Abstract

Abstract Cerebral microbleeds (CMBs) are small, focal brain lesions recognized as critical biomarkers of cerebrovascular disease and cognitive decline. Despite advances in MRI technology, detecting CMBs remains challenging, highlighting the need for automated tools. This study aimed to evaluate the standalone performance of Neurophet SCALE MRI for automated CMB detection. The model was trained on 201 SWI and phase examinations. Neurophet SCALE MRI employs a two-stage deep learning pipeline with preprocessing steps, including reorientation, resampling, and data augmentation. In the first stage, CMB candidates are generated using a multiscale backbone and bidirectional convolutional Long Short-Term Memory. The second stage reduces false positives through a Squeeze-and-Excitation ResNet-based classifier and brain tissue segmentation. In this retrospective, single-center clinical trial, the model was tested on 457 MRI examinations. The primary endpoints were lesion-wise sensitivity (> 85.7%) and false positive rate (< 2.35 per patient). In addition, patient-wise and group-wise analyses were conducted. A total of 456 participants (224 CMB-positive, 232 CMB-negative) with 515 CMB lesions were included for the statistical analysis. The device exceeded all predefined performance criteria, demonstrating a lesion-wise sensitivity of 88.35% (95% CI: 86.61–90.17) and a false positive rate of 0.95 per patient (95% CI: 0.83–1.07). Patient-wise sensitivity and specificity were 1.0 (95% CI: 0.98–1.0) and 0.86 (95% CI: 0.81–0.90), respectively. For group-wise classification (0–4 vs. ≥5 CMBs), sensitivity and specificity were 0.91 (95% CI: 0.88–0.93) and 0.95 (95% CI: 0.74–1.0). Neurophet SCALE MRI demonstrated high sensitivity and specificity along with a low false-positive rate, supporting its potential clinical utility. Further validation by expert readers in a broader population is warranted.

Scientific Reports
Intracerebral and Subarachnoid Hemorrhage Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon